<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Trial id="175339"><TitleDisplay>Combination Chemotherapy in Treating Patients With Bladder Cancer</TitleDisplay><TitleOfficial>MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00005047</Identifier><Identifier type="Organisational Study">CDR0000067639</Identifier><Identifier type="Secondary Organisational">LAC-USC-4B951</Identifier><Identifier type="Secondary Organisational">SWOG-4B951</Identifier><Identifier type="Secondary Organisational">NCI-G00-1715</Identifier><Identifier type="Secondary Organisational">NYU-9852</Identifier><Identifier type="Secondary Organisational">CAN-NCIC-BL10</Identifier><Identifier type="Secondary Organisational">CCCWFU-88198</Identifier><Identifier type="Other">U10CA032102</Identifier><Identifier type="Trial Acronym">p53-MVAC</Identifier></Identifiers><Indications><Indication id="2380">Bladder cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="9" role="Therapeutic effect marker" type="Genomic;Proteomic">Cellular tumor antigen p53</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><Intervention type="InterventionPrimary"><Name>vinblastine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1028858" type="Company"><TargetEntity id="5011576955" type="organizationId">Southwest Oncology Group</TargetEntity></SourceEntity><SourceEntity id="1053488" type="Company"><TargetEntity id="5035526133" type="organizationId">NCIC Clinical Trials Group</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="20673" type="Company"><TargetEntity id="4297574348" type="organizationId">University of Southern California</TargetEntity></SourceEntity><SourceEntity id="2380" type="ciIndication"><TargetEntity id="C67" type="ICD10"/><TargetEntity id="188.9" type="ICD9"/><TargetEntity id="10005003" type="MEDDRA"/><TargetEntity id="-2101107804" type="omicsDisease"/><TargetEntity id="578" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><NumberOfSites>76</NumberOfSites><CompaniesSponsor><Company id="1028858">Southwest Oncology Group</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1053488">NCIC Clinical Trials Group</Company><Company id="20519">National Cancer Institute</Company><Company id="20673">University of Southern California</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>521</PatientCountEnrollment><PatientCountEvaluable>102</PatientCountEvaluable><DateStart>1997-08-31T00:00:00Z</DateStart><DateEnd type="actual">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T17:37:53Z</DateChangeLast><DateAdded>2014-03-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Toronto Sunnybrook Regional Cancer Centre</Affiliation><Name>Laurence H. Klotz, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University of Southern California</Affiliation><Name>Richard J. Cote, MD, FRCPath</Name></Contact><Contact type="Scientific contact"><Affiliation>Baylor College of Medicine</Affiliation><Name>Seth P Lerner, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically proven organ confined transitional cell carcinoma (TCC) of the bladder&lt;ul&gt;&lt;li&gt;Must have undergone radical cystectomy and bilateral pelvic lymphadenectomy with pathological stage from definitive cystectomy specimen of P1, P2a, or P2b and N0, M0 TCC with or without squamous/glandular differentiation (no adenocarcinoma, squamous cell carcinoma, or small cell carcinoma)&lt;/li&gt;&lt;li&gt;Margins must be negative for invasive or in situ TCC&lt;/li&gt;&lt;li&gt;In situ TCC in the urethra or ureter(s) allowed provided margins are negative&lt;/li&gt;&lt;li&gt;Clinical stage T1, T2a, or T2b based on transurethral resection bladder tumor specimen with P0 or PIS and N0, M0 TCC allowed&lt;/li&gt;&lt;li&gt;Incidental pT2a (Gleason score no &gt; 7), pT2b (Gleason score no &gt; 7), or pT2c (Gleason score no &gt; 7) adenocarcinoma of the prostate allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No invasive tumor into ureter(s) or urethra&lt;/li&gt;&lt;li&gt;Must have potentially curable disease&lt;/li&gt;&lt;li&gt;Must register within 9 weeks after surgery&lt;/li&gt;&lt;li&gt;No metastatic disease by physical exam and chest X-ray or CT scan of the chest&lt;/li&gt;&lt;li&gt;Eligible for randomization if:&lt;ul&gt;&lt;li&gt;p53 gene alteration present&lt;/li&gt;&lt;li&gt;Randomization occurs within 10 weeks after surgery&lt;/li&gt;&lt;li&gt;Those who are randomized to receive (MVAC) methotrexate, vinblastine, doxorubicin, and cisplatin begin MVAC within 12 weeks after cystectomy&lt;/li&gt;&lt;li&gt;No metastatic disease by physical exam and chest X-ray or CT scan of the chest&lt;/li&gt;&lt;li&gt;No prohibitive medical risk for chemotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Age:&lt;ul&gt;&lt;li&gt;Any age&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Performance status:&lt;ul&gt;&lt;li&gt;ECOG 0 to 1 or&lt;/li&gt;&lt;li&gt;Karnofsky 70 to 100%&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Life expectancy:&lt;ul&gt;&lt;li&gt;Not specified&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;WBC at least 4000/mm3&lt;/li&gt;&lt;li&gt;Platelet count at least 150,000/mm3&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;SGOT or SGPT no &gt; 2 x normal&lt;/li&gt;&lt;li&gt;Alkaline phosphatase no &gt; 2 x normal&lt;/li&gt;&lt;li&gt;Bilirubin normal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine no &gt; 1.8 mg/dl&lt;/li&gt;&lt;li&gt;Creatinine clearance at least 50 ml/min&lt;/li&gt;&lt;li&gt;Blood urea nitrogen normal&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular:&lt;ul&gt;&lt;li&gt;No serious arrhythmias&lt;/li&gt;&lt;li&gt;No congestive heart disease with New York Heart Association class III or IV status&lt;/li&gt;&lt;li&gt;Randomization group:&lt;/li&gt;&lt;li&gt;Ejection fraction must be at least 50% by MUGA scan if there is a clinical concern regarding the patient's cardiac status&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;No other malignancy (including synchronous papillary or invasive upper urinary tract malignancy) within the past five years except incidental prostate cancer (found at cystectomy), basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix&lt;/li&gt;&lt;li&gt;No concurrent advanced medical illness or psychological disease&lt;/li&gt;&lt;li&gt;No prohibitive medical risk for chemotherapy&lt;/li&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy&lt;ul&gt;&lt;li&gt;Not specified&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Chemotherapy&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;No prior systemic chemotherapy for bladder cancer&lt;/li&gt;&lt;li&gt;At least five years since other prior systemic chemotherapy&lt;/li&gt;&lt;li&gt;Prior intravesical therapy allowed&lt;/li&gt;&lt;li&gt;Randomization group:&lt;/li&gt;&lt;li&gt;Prior intravesical therapy allowed if administered prior to cystectomy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy&lt;ul&gt;&lt;li&gt;Not specified&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Radiotherapy&lt;ul&gt;&lt;li&gt;No prior pelvic irradiation&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Surgery&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Probability of Recurring: p53 positive patients randomized to MVAC (arm I) compared to p53 positive patients randomized to observation (arm II). Time from registration to the first observation of disease recurrence, censoring patients who died of unrelated causes. Probabilities of recurring were based on cumulative incidence curves. Recurrence is defined as first radiological appearance of bladder cancer, per local standard of care</Description><Timeframe>Five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Probability of Recurrence: patients with tumors demonstrating alteration in p53 compared to patients with no p53 alterations. Probabilities of recurring were based on cumulative incidence curves. Recurrence is defined as first radiological appearance of bladder cancer, per local standard of care</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Probability of Overall Survival: patients with tumors demonstrating alteration in p53 compared to patients with no p53 alterations. Probabilities of survival were based on the Kaplan-Meier product-limit method</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Probability of Overall Survival: p53 positive patients randomized to MVAC (arm I) compared to p53 positive patients randomized to observation (arm II). Survival is calculated from registration to death due to any cause. Probabilities of survival were based on the Kaplan-Meier product-limit method</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This randomized, phase III trial was studying combination chemotherapy to see how      well it works compared to observation alone in treating patients with bladder cancer.&lt;/para&gt;&lt;para&gt;The objectives of the study were:&lt;br/&gt;Compare the recurrence-free and overall survival in patients with transitional cell carcinoma of the bladder with p53 gene alterations treated with methotrexate, vinblastine, doxorubicin, and cisplatin versus observation alone. &lt;br/&gt;Compare the recurrence-free and overall survival in patients with or without p53 gene alterations treated with observation alone. &lt;br/&gt;Examine the expression of p53 and other genes, particularly RB, p21, and p16, involved in cell cycle regulation that might be involved in the response to chemotherapy in these patients. &lt;br/&gt;Correlate p53 mutational gene status with p53 protein expression by immunohistochemistry, outcome (recurrence-free and overall survival), response to chemotherapy, and expression of key molecules in the p53-mediated apoptotic pathway in patients treated with this regimen versus observation alone.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 2015, the results from post hoc analysis of this prospective clinical trial, evaluating the association between lymphovascular invasion (LVI) and clinical outcome in organ-confined, node-negative urothelial cancer of the bladder (UCB) in the subset of patients whose tumors exhibited LVI  (n = 102). There was a significant association between LVI and time to recurrence (TTR; p = 0.01) and with overall survival (OS; p = 0.001) after adjustment for pathological stage. However, LVI was not significantly associated with TTR and OS (p = 0.65 and 0.26, respectively) in 27 patients with LVI-positive tumors who were randomized to receive adjuvant chemotherapy with MVAC [&lt;ulink linkType="Reference" linkID="1686883"&gt;1686883&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be  assigned to one of two treatment      groups based on the status of the p53 gene in the bladder tumor.&lt;br/&gt;Group A (p53 gene alteration, defined by &amp;gt; 10% nuclear reactivity): patients           would be   stratified according to age (under 65 versus 65 and over), stage (P1 versus P2a versus P2b),           grade (1 or 2 versus 3 or 4), and p21 status. Patients would be   randomized to one of two treatment           arms within 10 weeks after radical cystectomy and bilateral pelvic lymphadenectomy and           within 2 weeks after registration.&lt;br/&gt;Arm I: within 2 weeks after randomization, patients would receive methotrexate iv on                days 1, 15, and 22; vinblastine iv on days 2, 15, and 22; and doxorubicin iv and                cisplatin iv on day 2. Treatment would be   repeated every 4 weeks for three courses in the                absence of disease progression or unacceptable toxicity.&lt;br/&gt;Arm II: patients would undergo observation for recurrence but do not receive adjuvant                chemotherapy after surgery.&lt;br/&gt;Patients who were eligible for randomization but decline to be randomized would be undergo observation      for recurrence.&lt;br/&gt;Group B (p53 gene normal, defined by &amp;lt; 10% nuclear reactivity): patients           would bundergo observation for recurrence but did not receive adjuvant chemotherapy after           surgery.&lt;br/&gt;Patients would be   followed every 6 months for five years and then annually thereafter.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) [&lt;ulink linkType="Reference" linkID="1686883"&gt;1686883&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility analysis.                                                    &lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M4N 3M5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Address1>Calgary</Address1><Contacts/></Site><Site><Name>Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women s College Health Sciences Centre</Name><Address1>Toronto</Address1><Address3> M4N 3M5</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Associates in Womens Health, P.A. - North Review</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67203</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Banner Good Samaritan Medical Center</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85006</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Banner Thunderbird Medical Center</Name><Address1>Glendale</Address1><Address2>Arizona</Address2><Address3>85306</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Big Sky Oncology</Name><Address1>Great Falls</Address1><Address2>Montana</Address2><Address3>59405</Address3><CountrySubDivision code="MT">Montana</CountrySubDivision><Contacts/></Site><Site><Name>Brooke Army Medical Center</Name><Address1>Fort Sam Houston</Address1><Address2>Texas</Address2><Address3>78234</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Dayton</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45429</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - St. Louis-Cape Girardeau</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3>63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Virginia Mason Research Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Western Regional, Arizona</Name><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85006</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - Wichita</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67214</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Care Northwest - Spokane South</Name><Address1>Spokane</Address1><Address2>Washington</Address2><Address3>99202</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Chanute</Name><Address1>Chanute</Address1><Address2>Kansas</Address2><Address3>66720</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Dodge City</Name><Address1>Dodge City</Address1><Address2>Kansas</Address2><Address3>67801</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - El Dorado</Name><Address1>El Dorado</Address1><Address2>Kansas</Address2><Address3>67042</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Kingman</Name><Address1>Kingman</Address1><Address2>Kansas</Address2><Address3>67068</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Medical Arts Tower</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67208</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Newton</Name><Address1>Newton</Address1><Address2>Kansas</Address2><Address3>67114</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Parsons</Name><Address1>Parsons</Address1><Address2>Kansas</Address2><Address3>67357</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Pratt</Name><Address1>Pratt</Address1><Address2>Kansas</Address2><Address3>67124</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Salina</Name><Address1>Salina</Address1><Address2>Kansas</Address2><Address3>67042</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Wellington</Name><Address1>Wellington</Address1><Address2>Kansas</Address2><Address3>67152</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Wichita</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67214</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Center of Kansas, P.A. - Winfield</Name><Address1>Winfield</Address1><Address2>Kansas</Address2><Address3>67156</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Therapy and Research Center</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</Name><Address1>Maywood</Address1><Address2>Illinois</Address2><Address3>60153</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Charles F. Kettering Memorial Hospital</Name><Address1>Kettering</Address1><Address2>Ohio</Address2><Address3>45429</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Cleveland Clinic - Wooster</Name><Address1>Wooster</Address1><Address2>Ohio</Address2><Address3>44691</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Cleveland Clinic Taussig Cancer Center</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44195</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital</Name><Address1>Parkersburg</Address1><Address2>West Virginia</Address2><Address3>26102</Address3><CountrySubDivision code="WV">West Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Community Oncology Group at Cleveland Clinic Cancer Center</Name><Address1>Independence</Address1><Address2>Ohio</Address2><Address3>44131</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>David C. Pratt Cancer Center at St. John's Mercy</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3>63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>David L. Rike Cancer Center at Miami Valley Hospital</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45409</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Feist-Weiller Cancer Center at Louisiana State University Health Sciences</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><Address3>71130-3932</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Fred Hutchinson Cancer Research Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98109-1024</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Good Samaritan Hospital</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45406</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Good Samaritan Regional Health Center</Name><Address1>Mount Vernon</Address1><Address2>Illinois</Address2><Address3>62864</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Grandview Hospital</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45405</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Group Health Central Hospital</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98104</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Harborview Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98104</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Herbert Irving Comprehensive Cancer Center at Columbia University</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10032</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>James P. Wilmot Cancer Center at University of Rochester Medical Center</Name><Address1>Rochester</Address1><Address2>New York</Address2><Address3>14642</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>McKee Medical Center</Name><Address1>Loveland</Address1><Address2>Colorado</Address2><Address3>80539</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Middletown Regional Hospital</Name><Address1>Middletown</Address1><Address2>Ohio</Address2><Address3>45044</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>North Colorado Medical Center</Name><Address1>Greeley</Address1><Address2>Colorado</Address2><Address3>80631</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>North Puget Oncology at United General Hospital</Name><Address1>Sedro-Woolley</Address1><Address2>Washington</Address2><Address3>98284</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Olympic Hematology and Oncology</Name><Address1>Bremerton</Address1><Address2>Washington</Address2><Address3>98310</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Ruth G. McMillan Cancer Center at Greene Memorial Hospital</Name><Address1>Xenia</Address1><Address2>Ohio</Address2><Address3>45385</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Saint Anthony's Hospital at Saint Anthony's Health Center</Name><Address1>Alton</Address1><Address2>Illinois</Address2><Address3>62002</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Salina Regional Health Center</Name><Address1>Salina</Address1><Address2>Kansas</Address2><Address3>67401</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Samaritan North Cancer Care Center</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45415</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Sentara Cancer Institute at Sentara Norfolk General Hospital</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23507</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Skagit Valley Hospital Cancer Care Center</Name><Address1>Mount Vernon</Address1><Address2>Washington</Address2><Address3>98273</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Sletten Regional Cancer Institute</Name><Address1>Great Falls</Address1><Address2>Montana</Address2><Address3>59405</Address3><CountrySubDivision code="MT">Montana</CountrySubDivision><Contacts/></Site><Site><Name>Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital</Name><Address1>Cape Girardeau</Address1><Address2>Missouri</Address2><Address3>63701</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Southwest Medical Center</Name><Address1>Liberal</Address1><Address2>Kansas</Address2><Address3>67901</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>St. Francis Hospital and Health Centers - Beech Grove Campus</Name><Address1>Beech Grove</Address1><Address2>Indiana</Address2><Address3>46107</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>St. Francis Medical Center</Name><Address1>Cape Girardeau</Address1><Address2>Missouri</Address2><Address3>63701</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>St. Joseph Hospital Community Cancer Center</Name><Address1>Bellingham</Address1><Address2>Washington</Address2><Address3>98225</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Swedish Cancer Institute at Swedish Medical Center - First Hill Campus</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98114</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>USC/Norris Comprehensive Cancer Center and Hospital</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90089-9181</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>UVMC Cancer Care Center at Upper Valley Medical Center</Name><Address1>Troy</Address1><Address2>Ohio</Address2><Address3>45373-1300</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>University Cancer Center at University of Washington Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98195-6043</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>University Hospital - San Antonio</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>University of Michigan Comprehensive Cancer Center</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3>48109-0942</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>University of Texas Health Science Center at San Antonio</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78284-7811</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Veterans Affairs Medical Center - Dayton</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45428</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Veterans Affairs Medical Center - Kansas City</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3>64128</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Veterans Affairs Medical Center - San Antonio (Murphy)</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78209</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Veterans Affairs Medical Center - Shreveport</Name><Address1>Shreveport</Address1><Address2>Louisiana</Address2><Address3>71101</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Via Christi Cancer Center at Via Christi Regional Medical Center</Name><Address1>Wichita</Address1><Address2>Kansas</Address2><Address3>67214</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Wenatchee Valley Clinic</Name><Address1>Wenatchee</Address1><Address2>Washington</Address2><Address3>98801</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Wilford Hall Medical Center</Name><Address1>Lackland Air Force Base</Address1><Address2>Texas</Address2><Address3>78236</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>William Beaumont Hospital - Royal Oak Campus</Name><Address1>Royal Oak</Address1><Address2>Michigan</Address2><Address3>48073</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>CCOP - St. Louis - Cape Girardeau</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3> 63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Cleveland Clinic - Taussig Cancer Center</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3> 44195</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>David C. Pratt Cancer Center at St. John s Mercy</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3> 63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Fred Hutchinson Cancer Research Center - University of Washington Cancer Consortium</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3> 98109</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Grand View Hospital</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3> 45405</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>Saint Anthony s Hospital at Saint Anthony s Health Center</Name><Address1>Alton</Address1><Address2>Illinois</Address2><Address3> 62002</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>USC - Norris Comprehensive Cancer Center and Hospital</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90089-9181</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of Michigan - Comprehensive Cancer Center</Name><Address1>Ann Arbor</Address1><Address2>Michigan</Address2><Address3> 48109-0942</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bladder cancer</Disease><PatientSegments><PatientSegment><PatientSegment id="7805">Subjects with Muscle Invasive Bladder Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7806">Subjects with Locally Advanced Bladder Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7807">Subjects with Stage II Bladder Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8092">Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8095">Subjects with Stage I Bladder Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00005047</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bladder cancer" id="11789"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Bladder cancer" id="11792">Assessment of time to recurrence</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bladder cancer" id="11717"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bladder cancer" id="7436"><Criterion>Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7439"><Criterion>Subjects with Muscle Invasive Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7440"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7442"><Criterion>Subjects with Stage I Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7443"><Criterion>Subjects with Stage II Bladder Cancer</Criterion></Inclusion><Inclusion disease="Bladder cancer" id="7463"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7464">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Bladder cancer" id="7465">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Bladder cancer" id="7470">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bladder cancer" id="7472"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7478">Subjects with history of/scheduled for surgery/procedure for bladder cancer</SubCriterion><SubCriterion disease="Bladder cancer" id="12898">Subjects with history of/scheduled for transurethral resection (TUR)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bladder cancer" id="7484"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7485">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Bladder cancer" id="7486">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Bladder cancer" id="7488">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bladder cancer" id="34031"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="7487">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bladder cancer" id="9003"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bladder cancer" id="9030"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="9031">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bladder cancer" id="9041"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion><Exclusion disease="Bladder cancer" id="26361"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="9016">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bladder cancer" id="26372"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Bladder cancer" id="8991">Subjects with Metastatic Bladder Cancer</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2007-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>122.03 Months</EnrollmentPeriod><EnrollmentRate>4.27 Patients/Month</EnrollmentRate><DateFirstReceived>2000-04-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-03-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-25T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial>